Debiopharm invests in remote cancer patient symptom monitoring for personalized care with Carevive Series C financing round

Our digital health investment team is excited to announce their latest investment in the Miami-headquartered digital health company Carevive, a health-tech start-up specializing in cancer care management and decision support.

Debiopharm Iinvested in the startup Carevive


This Florida based start-up has developed a patient care management tool that collects oncology patient reported outcomes, their ongoing experience, following patients through post-treatment into survivorship. The company is currently building 16 cancer-specific patient experience databases to enable providers to continuously improve patient care, to allow patients to receive better access to novel therapies of the future, and to improve clinical trial design efficiency. Healthcare providers can use Carevive software embedded in their EMR workflows to generate personalized patient care plans and to remotely monitor and manage patient symptoms at home.

“This series C financing round will enable the startup to grow their existing business and build tumor-specific registries with symptom, patient experience and clinical EMR data.”
– Cedric Odje, Investment Analyst.

Other than Debiopharm, Carevive announced receiving additional Series C funding from co-investors such as Philips Health Technology Ventures, Cerner Capital, HLM Venture Partners, LRVHealth, and Co-Founder/CEO Madelyn Trupkin Herzfeld.

Carevive is focused on understanding and improving the cancer patient experience, to deliver better quality cancer care with improved outcomes. The registries created by this health tech solution can be used by the pharmaceutical industry to gather post-market regulatory data, to better understand the use of marketed products, and offer key insights for smarter drug development. Visit the Carevive site to learn more.

“This tool will facilitate the integration of patient-reported symptoms, experience, and preferences for better informed treatment decisions.”
– Tom Gibbs, Director of Debiopharm’s digital health fund.

Click here to access to CAREVIVIE press release.